| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | P2RY2 |
| Uniprot No | P41231 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-377aa |
| 氨基酸序列 | MAADLGPWNDTINGTWDGDELGYRCRFNEDFKYVLLPVSYGVVCVPGLCLNAVALYIFLCRLKTWNASTTYMFHLAVSDALYAASLPLLVYYYARGDHWPFSTVLCKLVRFLFYTNLYCSILFLTCISVHRCLGVLRPLRSLRWGRARYARRVAGAVWVLVLACQAPVLYFVTTSARGGRVTCHDTSAPELFSRFVAYSSVMLGLLFAVPFAVILVCYVLMARRLLKPAYGTSGGLPRAKRKSVRTIAVVLAVFALCFLPFHVTRTLYYSFRSLDLSCHTLNAINMAYKVTRPLASANSCLDPVLYFLAGQRLVRFARDAKPPTGPSPATPARRRLGLRRSDRTDMQRIEDVLGSSEDSRRTESTPAGSENTKDIRL |
| 预测分子量 | 42,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于P2RY2重组蛋白的参考文献及其摘要概括：
1. **文献名称**：*Recombinant human P2Y2 receptor activity in airway epithelial cells*
**作者**：Lazarowski ER, et al.
**摘要**：研究利用重组人P2Y2受体在气道上皮细胞中表达，发现其激活后通过IP3/Ca²⁺信号通路促进黏蛋白分泌，提示其在囊性纤维化治疗中缓解黏液阻塞的潜力。
2. **文献名称**：*P2Y2 receptor agonists enhance wound epithelialization through promoting keratinocyte migration*
**作者**：Boucher RC, et al.
**摘要**：通过重组P2Y2受体实验，发现其激动剂(如UTP)可激活ERK1/2通路，显著加速表皮角质细胞迁移和伤口愈合，为慢性创面治疗提供新靶点。
3. **文献名称**：*Structural insights into the human P2Y2 receptor signaling via a recombinant expression system*
**作者**：Zhang Y, et al.
**摘要**：利用昆虫细胞重组表达系统解析P2Y2受体三维结构，揭示其与核苷酸配体(ATP/UTP)的结合模式及β-arrestin信号偏向性激活机制，助力选择性药物设计。
---
**备注**：P2RY2作为G蛋白偶联受体，其重组蛋白研究多聚焦于呼吸道疾病(如黏液清除)、组织修复及结构药理学领域。近年研究倾向于开发受体特异性激动剂/拮抗剂，或结合冷冻电镜技术优化靶向药物设计。
**Background of Recombinant P2RY2 Protein**
P2RY2. a member of the purinergic receptor family, is a G protein-coupled receptor (GPCR) that binds extracellular nucleotides such as ATP and UTP. It plays a critical role in mediating cellular responses to tissue stress or damage by regulating processes like inflammation, ion transport, and cell proliferation. The P2RY2 receptor is widely expressed in epithelial, immune, and endothelial cells, where it activates intracellular signaling pathways, including Gq-mediated phospholipase C (PLC) activation, leading to increased intracellular calcium levels and downstream effects on mitogen-activated protein kinases (MAPK) and NF-κB pathways.
Recombinant P2RY2 protein is engineered in vitro using expression systems (e.g., mammalian, insect, or bacterial cells) to produce a purified, functional form of the receptor for research and therapeutic applications. This engineered protein retains ligand-binding specificity and signaling activity, enabling studies on receptor-ligand interactions, pathway modulation, and drug discovery. Its applications span investigating roles in diseases like cystic fibrosis, dry eye syndrome, and cancers, where dysregulated purinergic signaling contributes to pathology.
Recent studies highlight recombinant P2RY2's potential as a therapeutic target, with agonists/antagonists explored for treating fibrotic disorders, chronic inflammation, and respiratory conditions. Additionally, it serves as a tool for structural biology to resolve GPCR activation mechanisms and design targeted therapies. Challenges remain in optimizing receptor stability and signaling fidelity in recombinant forms, but advances in protein engineering continue to enhance its utility in both basic and translational research.
×
